Get the Stockscreener App
23.93
1.77%
-0.43
After Hours:
23.94
0.01
+0.04%
Beam Therapeutics Inc stock is traded at $23.93, with a volume of 2.29M.
It is down -1.77% in the last 24 hours and up +2.22% over the past month.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
See More
Previous Close:
$24.36
Open:
$21.62
24h Volume:
2.29M
Relative Volume:
2.75
Market Cap:
$1.97B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-5.306
EPS:
-4.51
Net Cash Flow:
$-153.40M
1W Performance:
+7.94%
1M Performance:
+2.22%
6M Performance:
+3.46%
1Y Performance:
-2.29%
1-Day Range:
$21.46
$24.79
1-Week Range:
$21.46
$24.95
52-Week Range:
$18.85
$49.50
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
| Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-13-22 | Initiated | Citigroup | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Jan-05-22 | Initiated | Guggenheim | Buy |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Sep-24-21 | Resumed | Stifel | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Redburn | Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-16-21 | Initiated | Wells Fargo | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Aug-05-20 | Initiated | William Blair | Outperform |
| Mar-02-20 | Initiated | Barclays | Overweight |
| Mar-02-20 | Initiated | JP Morgan | Overweight |
| Mar-02-20 | Initiated | Jefferies | Buy |
| Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
Beam Is Laser-Focused On ASH As It Reports Promising Sickle Cell Data, And A Death - Scrip
SCD phase I/II death shines Beam on ‘very real’ busulfan risk - BioWorld Online
Beam’s Base-Editing Sickle Cell Therapy Shows Early Promise, But a Fatality Overshadows Results - MedCity News
Gene Therapy Developer Beam Therapeutics Reports One Patient Death In Early-Stage Sickle Cell Disease Trial - Yahoo Finance
JPMorgan maintains $48 target on Beam Therapeutics stock - Investing.com
Stifel maintains $69 target on Beam Therapeutics stock - Investing.com
Beam Therapeutics' early base editing clinical data overshadowed by patient death - The Business Journals
Beam Therapeutics (NASDAQ:BEAM) Shares Gap Down Following Weak Earnings - MarketBeat
Beam Therapeutics sustains Outperform stock rating on clinical data - Investing.com
Beam Therapeutics (NASDAQ:BEAM) Announces Quarterly Earnings Results, Misses Estimates By $0.04 EPS - MarketBeat
Beam Therapeutics sustains Outperform stock rating on clinical data By Investing.com - Investing.com UK
Beam stock falls after fatality in gene editing trial - Seeking Alpha
Sickle cell patient dies in Beam study of base editing therapy - BioPharma Dive
Beam Therapeutics to Present Data Across Hematology - GlobeNewswire
Beam Therapeutics' Sickle Cell Treatment Shows Promising Results in First Clinical Trial | BEAM Stock News - StockTitan
Beam Therapeutics Inc Reports Q3 2024 EPS of $1.17, Revenue of $14.27 Million, Slightly Missing Estimates - GuruFocus.com
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
Beam Therapeutics Q3 24 Earnings Conference Call At 8:30 AM ET - Nasdaq
Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs - GlobeNewswire
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Shares Up 6.5%Still a Buy? - MarketBeat
Beam Therapeutics (BEAM) Stock Surges with Strong Trading Volume - GuruFocus.com
Beam Therapeutics's Earnings: A Preview - Benzinga
Beam Therapeutics (BEAM) Stock Surges Amid Market Activity - GuruFocus.com
Beam Therapeutics (BEAM): Promising Gene Editing Stock with Base Editing Technology - Insider Monkey
(BEAM) Investment Analysis - Stock Traders Daily
Beam Therapeutics (BEAM) Set to Announce Quarterly Earnings on Tuesday - MarketBeat
10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds - Insider Monkey
64,313 Shares in Beam Therapeutics Inc. (NASDAQ:BEAM) Bought by International Assets Investment Management LLC - MarketBeat
Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting - ForexTV.com
Beam Therapeutics to Hold Conference Call to Discuss Third - GlobeNewswire
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences - GlobeNewswire
We're Interested To See How Beam Therapeutics (NASDAQ:BEAM) Uses Its Cash Hoard To Grow - Yahoo Finance
Insufficient Growth At Beam Therapeutics Inc. (NASDAQ:BEAM) Hampers Share Price - Simply Wall St
Beam Therapeutics' SWOT analysis: base editing biotech stock faces pivotal year By Investing.com - Investing.com South Africa
Beam Therapeutics' SWOT analysis: base editing biotech stock faces pivotal year - Investing.com
Beam Therapeutics (BEAM): A Small-Cap Leader in Precision Genetic Medicine - Yahoo Finance
8 Best Small-Cap Growth Stocks to Buy According to Analysts - Insider Monkey
(BEAM) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Beam Therapeutics (BEAM): The Next Frontier in Biotech - TipRanks
State Street Corp's Strategic Acquisition in Beam Therapeutics Inc - Yahoo Finance
Beam Therapeutics (NASDAQ:BEAM) Trading Down 6.6% After Insider Selling - MarketBeat
Scotiabank Initiates Coverage of Beam Therapeutics (BEAM) with Sector Perform Recommendation - Nasdaq
Beam Therapeutics president sells $1.34 million in stock - Investing.com
Beam Therapeutics president sells $1.34 million in stock By Investing.com - Investing.com South Africa
Insider Selling: Beam Therapeutics Inc. (NASDAQ:BEAM) President Sells 51,110 Shares of Stock - MarketBeat
BEAM Crosses Above Key Moving Average Level - Nasdaq
Examining Beam Therapeutics Inc (BEAM) more closely is necessary - US Post News
Beam Therapeutics (NASDAQ:BEAM) Earns Sector Outperform Rating from Analysts at Scotiabank - MarketBeat
Beam Therapeutics Inc [BEAM] Investment Guide: What You Need to Know - Knox Daily
What is Beam Therapeutics Inc (BEAM) Stock Return on Shareholders’ Capital? - SETE News
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Beam Therapeutics Inc Stock (BEAM) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ciaramella Giuseppe | President |
Oct 14 '24 |
Sale |
26.27 |
51,110 |
1,342,752 |
160,260 |
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):